|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 September 2002, Vol. 100, No. 5, pp. 1575-1578
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Retrospective analysis of HHV-8 viremia and cellular viral
load in HIV-seropositive patients receiving interleukin 2 in
combination with antiretroviral therapy
Mauro Malnati,
Francesco Broccolo,
Silvia Nozza,
Loredana Sarmati,
Silvia Ghezzi,
Giuseppe Locatelli,
Fanny Delfanti,
Brunella Capiluppi,
Anna Careddu,
Massimo Andreoni,
Paolo Monini,
Guido Poli,
Adriano Lazzarin,
Paolo Lusso, and
Giuseppe Tambussi
From the Unit of Human Virology, AIDS
Immunopathogenesis Unit, DIBIT, and Clinic of Infectious Disease, San
Raffaele Scientific Institute, Milan, Italy; Department of Public
Health and Cellular Biology, University Tor Vergata, Rome, Italy;
Department of Pediatrics, University of Milan, Italy; and Laboratory of
Virology, Istituto Superiore di Sanita, Rome, Italy,
The combination of interleukin 2 (IL-2) and antiretroviral
therapy (ART) represents an emerging strategy in the treatment of
patients infected with HIV. Aside from its immunomodulatory role,
however, IL-2 may induce replication of human herpesvirus 8 (HHV-8)/Kaposi sarcoma (KS)-associated herpesvirus. We retrospectively evaluated HHV-8 plasma viremia and cellular load, as well as
anti-HHV-8 antibody titers, in sequential samples from 84 patients
receiving ART alone or in combination with IL-2. At baseline, HHV-8
plasma viremia was present only in 2 HHV-8-seropositive patients in
whom KS subsequently developed during or immediately after termination of IL-2 therapy. The level of viremia increased during follow-up and
peaked at the time of the clinical manifestation of KS. Moreover, transient peaks of HHV-8 viremia were temporally associated with administration of IL-2. HHV-8 plasma viremia was never detected in the
other 47 patients receiving IL-2 nor in 35 controls treated only with
ART. Thus, IL-2 therapy seems safe in most patients infected with both
HIV and HHV-8, except for those with detectable HHV-8 viremia, who may
not be eligible for IL-2 treatment.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
X. Zhang, J. F. Wang, B. Chandran, K. Persaud, B. Pytowski, J. Fingeroth, and J. E. Groopman
Kaposi's Sarcoma-associated Herpesvirus Activation of Vascular Endothelial Growth Factor Receptor 3 Alters Endothelial Function and Enhances Infection
J. Biol. Chem.,
July 15, 2005;
280(28):
26216 - 26224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Broccolo, G. Locatelli, L. Sarmati, S. Piergiovanni, F. Veglia, M. Andreoni, S. Butto, B. Ensoli, P. Lusso, and M. S. Malnati
Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids
J. Clin. Microbiol.,
December 1, 2002;
40(12):
4652 - 4658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
